[go: up one dir, main page]

CL2008002138A1 - Compuestos derivados de 6-cicloamino-3-(piridazin-4-il)imidazo[1,2-b]piridazina con actividad sobre la caseína quinasa 1 épsilon y/o 1 delta; procedimiento de preparación; composición farmacéutica; y uso para tratar trastornos del sueño, ritmo circadiano, alzheimer e hiperproliferanción de células. - Google Patents

Compuestos derivados de 6-cicloamino-3-(piridazin-4-il)imidazo[1,2-b]piridazina con actividad sobre la caseína quinasa 1 épsilon y/o 1 delta; procedimiento de preparación; composición farmacéutica; y uso para tratar trastornos del sueño, ritmo circadiano, alzheimer e hiperproliferanción de células.

Info

Publication number
CL2008002138A1
CL2008002138A1 CL2008002138A CL2008002138A CL2008002138A1 CL 2008002138 A1 CL2008002138 A1 CL 2008002138A1 CL 2008002138 A CL2008002138 A CL 2008002138A CL 2008002138 A CL2008002138 A CL 2008002138A CL 2008002138 A1 CL2008002138 A1 CL 2008002138A1
Authority
CL
Chile
Prior art keywords
cycloamino
pyridazin
imidazo
pyridazine
pharmaceutical composition
Prior art date
Application number
CL2008002138A
Other languages
English (en)
Inventor
Yulin Chiang
Philippe Burnier
Des Combes Sylvain Cote
Adrien Tak Li
Frederic Puech
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2008002138A1 publication Critical patent/CL2008002138A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos derivados de 6-cicloamino-3-(piridazin-4-il)imidazo[1,2-b]piridazina; composición farmacéutica que comprende a dichos compuestos; y su uso para tratar trastornos del sueño, del ritmo circadiano, enfermedades causadas por la hiperproliferación de células.
CL2008002138A 2007-07-19 2008-07-18 Compuestos derivados de 6-cicloamino-3-(piridazin-4-il)imidazo[1,2-b]piridazina con actividad sobre la caseína quinasa 1 épsilon y/o 1 delta; procedimiento de preparación; composición farmacéutica; y uso para tratar trastornos del sueño, ritmo circadiano, alzheimer e hiperproliferanción de células. CL2008002138A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95071107P 2007-07-19 2007-07-19
FR0705224A FR2918986B1 (fr) 2007-07-19 2007-07-19 Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
CL2008002138A1 true CL2008002138A1 (es) 2009-10-23

Family

ID=39183122

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002138A CL2008002138A1 (es) 2007-07-19 2008-07-18 Compuestos derivados de 6-cicloamino-3-(piridazin-4-il)imidazo[1,2-b]piridazina con actividad sobre la caseína quinasa 1 épsilon y/o 1 delta; procedimiento de preparación; composición farmacéutica; y uso para tratar trastornos del sueño, ritmo circadiano, alzheimer e hiperproliferanción de células.

Country Status (22)

Country Link
US (2) US8455491B2 (es)
EP (1) EP2178879B1 (es)
JP (1) JP5431319B2 (es)
KR (1) KR20100041771A (es)
CN (1) CN101784552A (es)
AR (1) AR069272A1 (es)
AU (1) AU2008300449A1 (es)
BR (1) BRPI0814510A2 (es)
CA (1) CA2693116A1 (es)
CL (1) CL2008002138A1 (es)
CO (1) CO6290690A2 (es)
EA (1) EA016376B1 (es)
ES (1) ES2429765T3 (es)
FR (1) FR2918986B1 (es)
MA (1) MA31616B1 (es)
NZ (1) NZ582683A (es)
PA (1) PA8789901A1 (es)
PE (1) PE20090493A1 (es)
TW (1) TW200914456A (es)
UY (1) UY31236A1 (es)
WO (1) WO2009037394A2 (es)
ZA (1) ZA201001214B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150567B2 (en) 2009-10-01 2015-10-06 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US9241924B2 (en) 2010-06-23 2016-01-26 Cymabay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2009014910A2 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
FR2939134A1 (fr) * 2008-12-01 2010-06-04 Sanofi Aventis Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
FR2940285A1 (fr) 2008-12-19 2010-06-25 Sanofi Aventis Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
FR2940284B1 (fr) * 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
PT2491038T (pt) * 2009-10-23 2016-07-14 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disubstituídos como modeladores de recetores de orexina
CA2778949C (en) 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US8710231B2 (en) 2010-08-09 2014-04-29 Pharmadesign, Inc. Inhibitor of casein kinase 1delta and casein kinase 1E
DK2835131T3 (en) 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
AU2012277912B2 (en) 2011-06-27 2017-03-23 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
CA2872216C (en) 2012-06-26 2021-07-20 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
CN104411314B (zh) 2012-07-09 2017-10-20 詹森药业有限公司 磷酸二酯酶10的抑制剂
US9475817B2 (en) 2012-12-21 2016-10-25 Bristol-Myers Squibb Company Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
US9556179B2 (en) 2012-12-21 2017-01-31 Bristol-Myers Squibb Company Substituted imidazoles as casein kinase 1 D/E inhibitors
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
RU2016132574A (ru) * 2014-01-09 2018-02-12 Интра-Селлулар Терапиз, Инк. Органические соединения
KR102559922B1 (ko) 2016-03-10 2023-07-25 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
EP3749667A1 (en) 2018-02-05 2020-12-16 Alkermes, Inc. Compounds for the treatment of pain
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
RS67259B1 (sr) 2019-09-19 2025-10-31 Novo Nordisk Healthcare Ag Kompozicije koje aktiviraju piruvat kinazu r (pkr)
US20230192699A1 (en) * 2020-03-27 2023-06-22 Gritscience Biopharmaceuticals Co., Ltd. Compounds as casein kinase inhibitors
CN115335057A (zh) * 2020-03-27 2022-11-11 北京原基华毅生物科技有限公司 抑制酪蛋白激酶的方法
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
AU2022367432A1 (en) 2021-10-14 2024-05-02 Incyte Corporation Quinoline compounds as inhibitors of kras

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001333A1 (en) * 1987-08-07 1989-02-23 The Australian National University IMIDAZO[1,2-b]PYRIDAZINES
ATE322016T1 (de) 1999-06-08 2006-04-15 Aventis Pharma Inc Screeningsverfahren zur änderung zirkadiane- rhythmus-eiweisse
JP4691506B2 (ja) 2003-12-11 2011-06-01 アベンティス・ファーマスーティカルズ・インコーポレイテツド カゼインキナーゼＩεの阻害剤としての置換１Ｈ−ピロロ［３，２−ｂ，３，２−ｃ，及び２，３−ｃ］ピリジン−２−カルボキシアミド及び関連類似物
EP1713784A1 (en) * 2004-02-12 2006-10-25 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
WO2007013673A1 (en) * 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150567B2 (en) 2009-10-01 2015-10-06 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US9241924B2 (en) 2010-06-23 2016-01-26 Cymabay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US10098843B2 (en) 2010-06-23 2018-10-16 Cymabay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine

Also Published As

Publication number Publication date
WO2009037394A2 (fr) 2009-03-26
US20130245023A1 (en) 2013-09-19
KR20100041771A (ko) 2010-04-22
CO6290690A2 (es) 2011-06-20
AR069272A1 (es) 2010-01-13
EA201070161A1 (ru) 2010-08-30
EA016376B1 (ru) 2012-04-30
NZ582683A (en) 2011-07-29
JP2010533686A (ja) 2010-10-28
CN101784552A (zh) 2010-07-21
AU2008300449A1 (en) 2009-03-26
UY31236A1 (es) 2009-03-02
US20100152157A1 (en) 2010-06-17
JP5431319B2 (ja) 2014-03-05
FR2918986A1 (fr) 2009-01-23
BRPI0814510A2 (pt) 2015-02-03
PE20090493A1 (es) 2009-05-27
US8455491B2 (en) 2013-06-04
FR2918986B1 (fr) 2009-09-04
WO2009037394A3 (fr) 2009-06-18
CA2693116A1 (fr) 2009-03-26
MA31616B1 (fr) 2010-08-02
ES2429765T3 (es) 2013-11-15
EP2178879A2 (fr) 2010-04-28
US9108971B2 (en) 2015-08-18
PA8789901A1 (es) 2009-02-09
ZA201001214B (en) 2011-05-25
EP2178879B1 (fr) 2013-07-03
TW200914456A (en) 2009-04-01

Similar Documents

Publication Publication Date Title
CL2008002138A1 (es) Compuestos derivados de 6-cicloamino-3-(piridazin-4-il)imidazo[1,2-b]piridazina con actividad sobre la caseína quinasa 1 épsilon y/o 1 delta; procedimiento de preparación; composición farmacéutica; y uso para tratar trastornos del sueño, ritmo circadiano, alzheimer e hiperproliferanción de células.
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
CL2011000973A1 (es) Compuestos derivados de pirazolo [1,5-a]pirimidina3-cabroxamida; composicion farmaceutica que los comprende, y uso para tratar o disminuir la gravedad de una enfermedad o condicion que responde a la inhibicion de la actividad de una jak quinasa.
CL2009000035A1 (es) Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
MY170189A (en) 6-cycloalkyl-1, 5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
SV2010003654A (es) Derivados biciclicos heterociclicos o espirobiciclicos heterociclicos enlazados, de pirazolo[1,5-a]pirimidinas, procedimientos para su preparacion y usos de los mismos
MX377802B (es) Metodos y composiciones para trastornos del sueño y otros trastornos.
MX2007004882A (es) Derivados de xantina con actividad de receptor de hm74a.
BR112013020605A2 (pt) derivados de 6-ciclobutil-1,5-diidro-pirazol[3,4-d]pirimidin-4-ona e seu uso como inibidores de pde9a
BR112015014752A2 (pt) compostos e métodos para modulação de cinase, e indicações para isto
BR112015023412A8 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso.
ATE526331T1 (de) Pyrrolopyrimidine für pharmazeutische zusammensetzungen
NZ630721A (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
SV2009003288A (es) Derivados de 2, 3-dihidroimidazo [1,2-c] quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
BR112014015720A8 (pt) derivados de tieno[3,2-d]pirimidina que têm atividade inibidora de proteinas quinases
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
BR112014027117A8 (pt) Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
BRPI0616264B8 (pt) composto 7-[2-[4-(6-flúor-3-metil-1,2-benzissoxazol-5- il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c]-pirimidin-5-amina, e, composição farmacêutica
BR112015019802A2 (pt) formulações farmacêuticas de nitrito e usos das mesmas
CL2012003360A1 (es) Compuestos derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1h)-dicarboxamida, inhibidores de caseína quinasa 1 épsilon y/o 1 delta; procedimiento de preparación; medicamento que los comprende; composición farmacéutica; y su uso para prevenir o tratar trastornos del sueño y del ritmo circadíano, y enfermedades inflamatorias.
CL2016001707A1 (es) Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11).